🛡️ Public data only — no PHI permitted on this instance.

About this page

Standardized IC-memo builder: thesis-element scoring with validation scores, diligence findings with severity/mitigation, the seven-lever value-creation bridge, and a final recommendation block suitable for submission authorization.

Source: data_public/ic_memo_generator.py (standardized memo template).

Investment Committee Memo Generator

Version v3.2 FINAL · Prepared 2026-04-14 · IC Meeting 2026-04-21 — 1,705 corpus deals

Deal

Project Azalea (

Sector

Gastroenterolo

$285M

EV/EBITDA

13.00x

Projected MOIC

2.78x

Projected IRR

22.7%

Expected MOIC

2.72x

(prob-wtd)

Corpus Deals

1,705

IC Recommendation
PROCEED — submit final bid
Full IC approval + investment sub-committee consent

Investment Thesis

Thesis Element	Description	Evidence	Validation Score
Platform Positioning	3rd-largest GI group in high-growth Sunbelt MSA	strong	88
M&A Opportunity	8-12 identified bolt-on targets in core + adjacent markets	moderate	72
Clinical Differentiation	Top-quartile quality metrics vs peers; anesthesia JV	strong	85
Payer Mix Quality	62% commercial; BCBS renewal 2027 provides price runway	moderate	70
Operating Leverage	22.5% EBITDA margin vs 18.5% sector P50 — upside to 26%	strong	82
Value Creation	RCM / scheduling / anesthesia JV optimizations quantified	strong	80
Management Team	Strong CEO with prior PE exit; CFO transitioning	moderate	68
Exit Optionality	Strategic buyers (GI Alliance, US Digestive) + sponsor demand	strong	85

Diligence Findings

Workstream	Finding	Severity	Mitigation	Impact
Financial QoE	Management adjustments $3.2M (one-time exec severance + refinancing)	clean	Independent QoE confirmed; minor normalization	no impact
Commercial	Top payer BCBS at 22% of revenue; renewal 2027	medium	Price reset leverage; relationship strong	2nd-payer development
Operational	Anesthesia model: W-2 vs 1099 classification risk	medium	Transition to W-2 post-close; $0.4M annualized cost	minor margin impact
Regulatory	2 OIG audits 2023 — closed no action	minor	Audit trail clean; proactive compliance program	no impact
Legal	3 pending malpractice suits — all covered by insurance	minor	Standard practice; reserves adequate	no impact
IT / Cyber	Epic instance at risk of mid-term migration forced by Epic EOL schedule	medium	Budget $2.5M for 18-month migration	integration cost
HR	Key-person concentration: 2 senior MDs, 35% of revenue	high	Long-term employment + equity; rollover negotiations	key-person risk
Antitrust	MSA concentration clears (CR3 42% pre → 48% post)	clean	Below 50% CR3 safety zone	no impact

Value Creation Levers — Target vs Probability-Weighted Expected

Value Creation Lever	Target ($M)	Base Rate ($M)	Probability	Timeline (mo)	Expected ($M)
Bolt-On M&A (8-12 practices)	$12.50	$8.80	75%	36	$9.40
Anesthesia JV Optimization	$3.80	$3.50	88%	12	$3.30
RCM / Billing Improvement	$2.50	$2.20	82%	18	$2.10
Payer Rate Uplift (BCBS 2027)	$1.80	$1.40	62%	24	$1.10
Supply Chain / GPO Consolidation	$0.85	$0.70	88%	12	$0.75
Operating Leverage (cost discipline)	$1.50	$1.20	78%	24	$1.20
Multiple Arbitrage (13x → 14.5x exit)	$13.50	$11.00	68%	60	$9.20

Risk Register

Risk	Category	Probability	Impact ($M)	Mitigation	Residual
Medicare rate cut (CRS / CMS annual)	Regulatory	medium	$3.50	Sensitivity built into model; 1% = $0.22M EBITDA	residual
CMS colonoscopy age-45 creates volume headwind	Regulatory	low	$0.50	Already reflected in CBO estimates; procedure mix shift	minimal
Key MD departure	Operational	medium	$6.50	Employment agreements + equity retention; identified successor pipeline	residual
BCBS 2027 renewal < market rate	Commercial	medium	$4.20	2nd payer development underway; relationship strong	residual
Integration cost overrun (EHR migration)	Operational	medium	$2.50	Budget reserve + seller indemnification	mitigated
Market entrance by GI Alliance competitor	Strategic	medium	$1.80	1st-mover advantage; tuck-in before competitor enters	monitor
Macro cap-ex lending rate increase	Financing	medium	$2.20	Fixed-rate term loan; minimal floating exposure	mitigated
DOJ qui tam / FCA post-close	Legal	low	$8.50	Compliance program; indemnification from seller	residual

Scenario Outcomes

Scenario	Exit EBITDA ($M)	Exit Multiple	Equity Proceeds ($M)	MOIC	IRR	Probability
Downside (base case -25%)	$31.50	11.00x	$285.00	1.50x	+8.5%	20%
Base Case	$42.00	13.00x	$488.00	2.78x	+22.7%	55%
Upside (base case +15%)	$48.30	14.00x	$595.00	3.38x	+27.7%	20%
Home Run (strategic / IPO)	$55.50	16.00x	$752.00	4.35x	+34.2%	5%

Deal Structure

Component	Amount ($M)	Terms	Notes
Purchase Price / EV	$285.00	13.0x LTM EBITDA	Include $2.5M WC adjustment
Cash at Close	$142.50	50% of EV	Committed financing signed
First-Lien Term Loan	$114.00	SOFR+475 / 7yr / cov-lite	Ares Capital / Golub
Second-Lien Term Loan	$28.50	SOFR+825 / 7yr / cov-lite	Owl Rock / Apollo
Seller Rollover	$14.25	5% equity; 2nd closing bite	Key MDs required
Management Equity	$14.25	Stub + PIK note on close	CEO + CFO + COO
Earnout	$11.40	4% over 24 months on EBITDA >$25M	Downside protection
Indemnification Reserve	$11.40	4% escrow over 18 months	Standard R&W insurance

IC Memo Summary: Project Azalea (GI Network SE) — Gastroenterology platform at $285M / 13.0x LTM EBITDA. Base case 2.78x MOIC / 22.7% IRR over 5.0y hold; probability-weighted expected 2.72x / 21.4%. Investment thesis validates to 79/100 — strong on platform positioning, operating leverage, exit optionality. Material findings mitigated via management transition, W-2 conversion budget, BCBS 2nd-payer development. Expected value creation $27.1M across 7 levers; multiple arbitrage (13x→14.5x) adds $9.2M; bolt-on M&A adds $9.4M. Recommend proceeding to final bid with submission authorization.